Advancing the Treatment and
Care of Transplant Patients
Advancing the Treatment and Care of Transplant Patients
3 Transplant Programs
20+ Clinical Trials
130+ Clinical Sites
Organ transplantation is the treatment for end-stage organ failure when other therapies have failed or are not available, and when the person affected by organ failure is deemed likely to benefit from transplantation. The benefits of organ transplantation, as evidenced by prolonged survival and/or improved quality of life, have been clearly demonstrated for children and adults. However, normal life expectancy and health-related quality of life are rarely, if ever, restored by organ transplantation. Although 1-year survival after organ transplantation has improved markedly over the last 15 years, there has been little success in reversing the decline in long-term graft and patient survival in recipients of an organ transplant.
The goal of NIAID transplantation research is to improve the long-term success of organ transplantation by understanding the role the immune system plays in transplant success or failure. NIAID-supported investigators are working to selectively control or eliminate unwanted immune responses while maintaining the immune system's ability to fight infection and cancer. The aim is to modify the immune response in a way that will improve long-term transplant survival and reduce the need for broadly immunosuppressive medications, which can cause significant side effects.
NIAID supports research that focuses on understanding the role the immune system plays in the success or failure of transplanted cells, tissues, and organs. Researchers are studying ways to selectively control or eliminate unwanted immune responses with the ultimate goal of enhancing long-term transplant survival.
CTOT-CA will conduct clinical research addressing the immunologic and infectious barriers to long-term success of transplantation in interventional trials (Phase I, II, or III) or observational clinical studies in organ transplantation (heart, kidney, lung, and liver). The goals of this research are to further our understanding of and ultimately reduce immune- and infection-mediated morbidity and mortality associated with organ transplantation.
The ITN conducts clinical trials, mechanistic studies, and assay development in transplantation with a focus on tolerogenic approaches to improve the long-term outcomes of allotransplantation. ITN Transplantation research priorities include innovative tolerogenic approaches to improve long-term graft survival and decrease the adverse immunologic consequences of allotransplantation and pharmacologic immunosuppression.
NIAID supports investigator-initiated clinical trials using the R01 or U01 funding mechanism. The IICT process was created to support a limited number of IICTs outside the existing clinical trial networks. Investigators can consult with NIAID in advance of grant submission to ensure research goals align with NIAID's mission.
Active and upcoming clinical trials are shown below. These can be filtered by transplant type, transplant program, patient population, and clinical trial status. For more information about a specific trial click on the links within each box.
Filter by:
Have questions about the NIAID transplant programs? Are you a member of a current transplant study and need to log in? Please see below.
Questions about a transplant program or need help?
Already a study team member and need to login?
This project is funded by the National Institute of Allergy and Infectious Diseases , National Institutes of Health